Article Versions Notes

Teixeira MF, Tomaz V, Barbosa e Silva LC, Donizete U, Tustumi F, Nakaya HI, Beal JR, Moura F, Borad MJ, Campregher PV, et al. Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy Outcomes. Biomedicines. 2026; 14(3):593. https://doi.org/10.3390/biomedicines14030593

Teixeira, Maria Fernanda, Victoria Tomaz, Lucas Campos Barbosa e Silva, Uelson Donizete, Francisco Tustumi, Helder Imoto Nakaya, Juliana Rodrigues Beal, Fernando Moura, Mitesh J. Borad, Paulo Vidal Campregher, and et al. 2026. "Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy Outcomes" Biomedicines 14, no. 3: 593. https://doi.org/10.3390/biomedicines14030593

Teixeira, M. F., Tomaz, V., Barbosa e Silva, L. C., Donizete, U., Tustumi, F., Nakaya, H. I., Beal, J. R., Moura, F., Borad, M. J., Campregher, P. V., & Uson Junior, P. L. S. (2026). Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy Outcomes. Biomedicines, 14(3), 593. https://doi.org/10.3390/biomedicines14030593